PT. Penta Valent Tbk (IDX:PEVE)
Indonesia · Delayed Price · Currency is IDR 314.00
-4.00 (-1.26%)
At close: Nov 5, 2026
PT. Penta Valent Tbk Financials Overview
Financials in millions IDR. Fiscal year is January - December.
Millions IDR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 3,780,178 | 3,547,994 | 3,012,741 | 2,484,676 | 2,147,333 | 1,788,027 |
Revenue Growth | 10.91% | 17.77% | 21.25% | 15.71% | 20.09% | 29.50% |
Gross Profit Gross Profit Growth | 414,686 | 375,066 | 348,099 | 301,025 | 228,853 | 166,070 |
Operating Income Operating Income Growth | 95,645 | 86,577 | 65,885 | 49,015 | 35,407 | 29,631 |
Net Income Net Income Growth | 58,176 | 55,327 | 48,012 | 36,172 | 23,547 | 19,276 |
Earnings Per Share EPS Growth | 32.91 | 31.75 | 27.55 | 20.76 | 20.56 | 27.54 |
EPS Growth | -4.19% | 15.24% | 32.73% | 0.95% | -25.33% | 7050.50% |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Pharmaceutical Product Pharmaceutical Product Growth | 2,935,777 | 2,868,700 | 2,527,372 | 2,148,463 | 1,933,437 | 1,584,946 |
Consumer Product Consumer Product Growth | 763,198 | 679,294 | 485,369 | 336,212 | 213,896 | 203,082 |
Total Total Growth | 3,698,975 | 3,547,994 | 3,012,741 | 2,484,676 | 2,147,333 | 1,788,027 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 14,626 | 15,063 | 7,784 | 4,492 | 5,688 | 3,484 |
Total Debt Total Debt Growth | 448,060 | 326,847 | 189,637 | 77,906 | 60,063 | 39,298 |
Net Cash (Debt) Net Cash Growth | -433,434 | -311,784 | -181,853 | -73,414 | -54,375 | -35,814 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -245.20 | -178.94 | -104.37 | -42.13 | -47.49 | -51.16 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -91,199 | -118,550 | -93,125 | -59,083 | -17,992 | -5,363 |
Capital Expenditures CapEx Growth | -3,485 | -4,718 | -3,261 | -6,370 | -1,575 | -4,099 |
Free Cash Flow Free Cash Flow Growth | -94,684 | -123,268 | -96,386 | -65,453 | -19,567 | -9,461 |
Free Cash Flow Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 10.97% | 10.57% | 11.55% | 12.12% | 10.66% | 9.29% |
Operating Margin | 2.53% | 2.44% | 2.19% | 1.97% | 1.65% | 1.66% |
Pretax Margin | 1.95% | 2.01% | 2.05% | 1.89% | 1.48% | 1.49% |
Profit Margin | 1.54% | 1.56% | 1.59% | 1.46% | 1.10% | 1.08% |
FCF Margin | -2.50% | -3.47% | -3.20% | -2.63% | -0.91% | -0.53% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 9.54 | 17.55 | 10.30 | 8.30 | - | - |
PS Ratio | 0.15 | 0.27 | 0.16 | 0.12 | - | - |